TDTrevor Duke

Trevor Duke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Trevor Duke has a total of 411 co-authors. Here are the top co-authors by number of shared publications:

  • Hamish R. Graham

    Centre for International Child Health, University of Melbourne, Melbourne, Victoria, Australia

    7 shared publications
  • Amy Gray

    Faculty of Medicine, Dentistry & Health Sciences The University of Melbourne Melbourne Victoria Australia

    6 shared publications
  • John D Vince

    Deputy Dean and Head of Research and Post-graduate studies School of Medicine and Health Sciences, University of Papua New Guinea, Port Moresby, Papua, Guinea

    6 shared publications
  • John Vince

    Department of Paediatrics, Port Moresby General Hospital, Papua, New Guinea

    6 shared publications
  • Nakapi Tefuarani

    ASchool of Medicine and Health Sciences, University of Papua New Guinea, Boroko, NCD, Papua New Guinea

    6 shared publications
  • Paulus Ripa

    Western Highlands Provincial Health Authority, Mount Hagen General Hospital, Papua New Guinea

    6 shared publications

Latest Publications

  • Hemodynamic Patterns Relative to Vasopressin Initiation and Subsequent Septic Shock Progression in Children: A Retrospective Cohort, 2020–2023

    by Ben Gelbart, Gabby Hall, Bradley G. Carter, Sam Marshall, Andrea Veysey, Sailavan Ramesh, Kate Masterson, Trevor Duke, Andrew Goodwin, Warwick Butt

    Objectives: To describe the hemodynamic patterns associated with starting vasopressin in children with septic shock and to compare the early patterns based on subsequent progression of shock. Design: Retrospective cohort (2020–2023) study. Setting: Single-center, tertiary PICU in Australia. Patients: Children younger than 18 years with septic shock. Interventions: None. Measurements and Main Results: Hemodynamic variables collected at 1-minute intervals during a 1-hour observation period after starting vasopressin infusion were reviewed and collated according to whether shock subsequently progressed in the following 5 hours. In a cohort of 30 children (median age, 9 yr [interquartile range, 2–14 yr]), eight had shock progression, which was defined by echocardiography, lactate, and use of extracorporeal support. Cases with subsequent shock progression, as opposedto not, had an associated higher Phoenix score (7 [7–8] vs. 6 [5–6]; p = 0.01). The vasopressin starting dose in the shock vs. nonshock progression groups was 0.03 U/kg/hr (0.02–0.06 U/kg/hr) vs. 0.02 U/kg/hr (0.02–0.04 U/kg/hr; p = 0.72). We failed to find an association between ventricular dysfunction at baseline and the shock progression group vs. no shock progression (4/6 vs. 7/18; mean difference, 28%; 95% CI, –16% to 71%; p = 0.36). In the shock progression group, earlier pulse pressure continued on a decreasing trajectory following vasopressin initiation, despite increasing systolic and diastolic blood pressures. In those without shock progression, pulse pressure increased marginally. The difference between groups in the median pulse pressures during the observation period was 7.5 mm Hg. Conclusions: In this hypothesis-generating, retrospective study of children with septic shock treated with vasopressin, subsequent shock progression was associated with early decreasing pulse pressure. Further studies are needed to test whether early changes in pulse pressure after starting vasopressin can be used as a potential marker of subsequent shock progression.

  • Open Access

    Persistent pulmonary hypertension of the newborn: clinical course, outcomes, and use of sildenafil at Port Moresby General Hospital

    by Merlisa Kuama, Gamini Vali, Roland Barnabas, Francis Pulsan, Trevor Duke

    Introduction: Persistent pulmonary hypertension of the newborn (PPHN) is characterized by high pulmonary vascular resistance during the transition phase from intra- to extra-uterine life. It can complicate birth asphyxia, meconium aspiration, sepsis, pneumonia and other perinatal insults. PPHN can be difficult for health care workers to diagnose and treat, particularly where echocardiography is unavailable. In a prospective study of neonates at the Port Moresby General Hospital in Papua New Guinea, we examined the diagnosis of PPHN, using clinical signs and pre- and post-ductal oxygen saturation (SpO2) gradient (delta saturation) measured by pulse oximetry. We describe the course, outcomes, and the use of sildenafil, a phosphodiesterase inhibitor that can reduce pulmonary vascular resistance. Methodology: Neonates > 35.5 weeks gestation with respiratory distress, hypoxemia (SpO2 < 90%) and a pulse oximetry oxygen saturation pre- and post-ductal gradient of > 5% were followed prospectively. Pre- and post-ductal saturation and clinical features were recorded, and a respiratory distress score (RDS) was calculated. Affected neonates received oxygen therapy, supportive care, and sildenafil (1–2 mg kg−1 every 6 hours). We recorded the delta saturation and RDS for the first 5 days and compared neonates who survived and those who died. Results: Forty-two neonates with PPHN were evaluated over 6 months, representing 5% of all admissions to the Special Care Nursery and 20% of all newborns with respiratory distress. Twelve newborns died (29% mortality rate), with the highest mortality among newborns with severe birth asphyxia (encephalopathy) and meconium aspiration syndrome. Following the initiation of sildenafil and nasal prong oxygen, 55% of neonates improved within 24 hours, with no apparent side effects. Mean ± s.d. duration of oxygen therapy and hospital stay were 5.6 ± 4.4 days and 7.7 ± 6.5 days, respectively. Conclusion: Sildenafil with oxygen and supportive care was associated with a positive outcome for a percentage of newborns affected by PPHN when intensive care and echocardiography were unavailable. Pre- and post-ductal oxygen saturations together with other clinical features can support the diagnosis of PPHN in resource-limited clinical settings. Standard protocols and improved access to echocardiography could enhance PPHN detection and management. Prevention measures will be necessary to reduce the morbidity and mortality of perinatal asphyxia and PPHN.

  • Point-of-care lactate adds to prediction of outcome in children with WHO emergency signs in a low- and middle-income setting

    by Clyde Kamo, Rupert Marcus, Francis Pulsan, Trevor Duke

    In 2014, the World Health Organization (WHO) published revised guidelines for paediatric Emergency Triage Assessment and Treatment (ETAT) [1,2]. These guidelines were developed for low resource set...

  • Open Access

    “In-Series” Continuous Renal Replacement Therapy and Therapeutic Plasma Exchange: Single-Center Retrospective Cohort, 2018–2022

    by Rachel H. Msc Williams, Bradley G. Carter, Mathilde MBiomedEng Escudie, Edward BBiomedSc Harcourt, Michael Bsc/Ba Zampetti, Hazel BHlthSc Low, Primrose BHlthSc Khumalo, Chloe BHlthSc Chan, Trevor Duke, Roberto Chiletti, et al.

    OBJECTIVES: To describe our use and experience with an “in-series” approach for patients requiring both continuous renal replacement therapy (CRRT) as well as therapeutic plasma exchange (TPE). DESIGN: Retrospective review of case notes. SETTING: General and cardiac PICUs at the Royal Children’s Hospital in Melbourne, VIC, Australia. PATIENTS: Children (0–18 yr old) requiring both CRRT and TPE between 2018 and 2022. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Twelve children were successfully and safely treated with 32 TPE sessions and 38 CRRT sessions with our in-series CRRT and TPE setup using a total of 20 extracorporeal circuits and 11 additional plasma filters or hemofilters. This represents a reduction of 71% in standard circuit usage. CONCLUSIONS: Our approach to providing “in-series” CRRT and TPE used existing access and circuits, a single device, and resulted in efficient treatments, reduced infection risk, reduced exposure to circuits, less hemodilution, and less blood product use. Small potential cost and waste reductions were also achieved. This approach was performed safely with no unexpected adverse events.


  • Open Access

    Timing and response to vasopressin in children in a paediatric intensive care unit

    by Ben Gelbart, Andrea Veysey, Sailavan Ramesh, Peter Summers, Saravanan Satkumaran, Luregn J. Schlapbach, Trevor Duke

    Objectives: To describe the patterns of vasopressin use and the effect of timing in critically ill children. Methods: Retrospective study between 2017 - 2023 in children less than 18 years old in a tertiary paediatric intensive care unit (PICU). Results: Vasopressin was administered in 453/10,750 (4%) of admissions and of these 453, 43% had congenital heart disease and 21% had sepsis. The median starting dose was 0.02 Units/kg/hr [IQR;0.02–0.04] and vasopressin was commenced 13.9 h [IQR;2.5–67.7] after admission. Vasopressin was commenced within 24 h of noradrenaline initiation in 406 admissions. The median time from noradrenaline to vasopressin initiation was 4 h [IQR 16.3–0.5] and the median noradrenaline dose at vasopressin initiation was 0.15 µg/k/min [IQR 0.1–0.25]. Noradrenaline was able to be reduced following initiation of vasopressin, irrespective of timing between the two drugs. In an exploratory, multivariable logistic regression analysis, shorter time between noradrenaline and vasopressin initiation, measured continuously, was associated with reduced mortality (adjusted OR 0.94 [95%CI 0.91–0.98]). Arrhythmias, gastrointestinal and limb ischaemia during admission were higher in children who received vasopressin. Conclusions: Vasopressin is administered to 4% of admissions to a large tertiary PICU; commonly in sepsis and congenital heart disease. After vasopressin initiation, noradrenaline dose decreased irrespective of timing after noradrenaline, however, earlier timing may be associated with reduced mortality.


  • International child health and humanitarian agencies: a short history of the last century and reflections on the era to come

    by Trevor Duke

    The existence of international agencies dedicated to the health and well-being of children has spanned only the last 100 years, and has coincided with unprecedented progress in child health. A brief history of these agencies is reviewed, the strategies they supported and the challenges they faced, in the context of the last turbulent century, and the current State of the World’s children. Ultimately, these agencies are as effective as the people who support them, and this is a role for paediatricians and child health workers everywhere.


  • Randomised trials in child and adolescent health in low- and middle-income countries in 2024–2025

    by Trevor Duke

    Each year hundreds of randomised controlled trials are conducted in low- and middle-income countries addressing issues in clinical paediatrics and in child and adolescent health. The topics are as diverse as the problems facing children around the world in 2025. This year, 600 trial publications were included in an annual compilation. Many of these studies build on pre-existing evidence and may lead to change in practice or policy. The 600 publications come from all regions of the world.


  • Open Access

    Australasian Bronchiolitis Guideline: 2025 Update

    by Meredith L. Borland, Kate Loveys, Franz E. Babl, Elizabeth Cotterell, Libby Haskell, Sharon O’bRien, Ed Oakley, Catherine L. Wilson, Jane Alsweiler, David Armstrong, et al.

    Aim: To provide updated evidence‐based clinical guidance in the management of infants with bronchiolitis presenting to emergency departments (EDs), general paediatric, or intensive care units (ICUs) in Australia and Aotearoa New Zealand (AoNZ) following the first publication in 2016.Method: The Paediatric Research in Emergency Departments International Collaborative (PREDICT) network guideline working group appraised, summarised, and updated evidence from 1 January 2000 to 24 January 2024 addressing 41 questions (30 from the 2016 guideline and 11 new questions for 2025). Recommendations were developed using GRADE methodology and revised after a period of external consultation.Results: The literature search identified 26 467 citations with 431 included in 41 recommendations providing 11 new and 7 key updates. The key changes included: (i) refinement of the clinical features of bronchiolitis, (ii) addition of new risk factors for severity of illness, (iii) advice on the role of biomarkers for unexpected deterioration or admission to ICU, (iv) guidance on glucocorticoids in SARS‐CoV‐2 co‐infection, (v) guidance on combined glucocorticoids/inhaled epinephrine in severe bronchiolitis requiring ICU level care, (vi) refinement of oxygen saturation targets, (vii) guidance on humidified high flow therapy and continuous positive airway pressure, (viii) recommendation on use of RSV prevention therapies/immunisations for babies and mothers.Conclusion: The updated Australasian Bronchiolitis Guideline provides clinicians across Australasian settings with the latest evidence‐based guidance on the management of the commonest condition in infancy requiring hospital admission.